Combining TAS-102 and Bevacizumab with Local Treatment for Advanced Colorectal Cancer

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This phase II clinical study evaluates the efficacy and safety of a sequential treatment approach using TAS-102 and bevacizumab combined with local treatment in patients with advanced colorectal cancer who have not responded to first-line therapy. A total of 119 patients will be randomized to receive either the new combination treatment or continue with standard second-line therapy. The primary goal is to assess the time to treatment failure, while secondary goals include overall response rate, disease control rate, progression-free survival, overall survival, safety, and patient-reported outcomes.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Unresectable colorectal adenocarcinoma confirmed by histopathology or cytology;
* Patients who have failed first-line standard therapy and are intended to receive second-line standard therapy;
* At least one measurable lesion according to RECIST 1.1 criteria;
* ECOG Performance Status 0-1;
* Estimated life expectancy ≥3months;
* Adequate major organ function;
* Subjects voluntarily participate in this study, sign the informed consent form, and have good compliance.

Exclusion Criteria:

* Allergy to the investigational drug and/or its excipients;
* Pregnant or lactating women;
* Prior treatment with TAS-102;
* Any CTCAE grade 2 or above toxicity caused by previous treatment that has not yet subsided (excluding alopecia, skin pigmentation, and chemotherapy-induced neurotoxicity);
* Known inherited or acquired bleeding (e.g., coagulopathy) or thrombophilia, as in patients with hemophilia; Current or recent (within 10 days before initiation of study treatment) use of a full-dose oral or injectable anticoagulant or thrombolytic agent for therapeutic purposes (prophylactic use of low-dose aspirin and low-molecular-weight heparin is allowed);
* Serious illness, including but not limited to the following:

  1. Patients with other malignant tumors within 5 years before enrollment, except basal cell carcinoma of the skin or carcinoma in situ of the cervix;
  2. Known brain and/or leptomeningeal metastases;
  3. Active infection or fever of unknown origin \> 38.5 ° C ;
  4. Poorly controlled hypertension (systolic blood pressure \>150 mmHg and/or diastolic blood pressure \>100 mmHg) with a previous history of hypertensive crisis or hypertensive encephalopathy;
  5. Known inherited or acquired bleeding (e.g., coagulopathy)
  6. Thrombotic or embolic events, such as cerebrovascular accident (including transient ischemic attack, cerebral hemorrhage, cerebral infarction), pulmonary embolism, etc., occurred within 6 months before the initiation of study treatment;
  7. Severe, unhealed or dehiscence wounds and active ulcers or untreated fractures;
  8. Myocardial infarction, severe/unstable angina, symptomatic congestive heart failure (NYHA Class III or IV) within the last 12 months;
  9. Acute or subacute intestinal obstruction, or chronic inflammatory bowel disease;
  10. There are serious psychological or psychiatric abnormalities that affect the compliance of patients to participate in this clinical study.
* Has undergone major surgical treatment (excluding diagnosis) within 4 weeks before the start of the study or is expected to undergo major surgical treatment during the study period;
* Inability to swallow pills, presence of malabsorption syndrome or any condition affecting gastrointestinal absorption;
* The investigator assessed that it is not appropriate to participate in the study.

Where it's running

• Fudan University Shanghai Cancer Center
  Shanghai, Shanghai Municipality, China Recruiting

Study contacts

• Study coordinator: Wenhua Li, Ph.D
• Email: whliiris@hotmail.com
• Phone: 8618017317210

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• SAR445877 with FOLFOX6 and bevacizumab as first-line treatment for MSS metastatic colorectal cancer

  This study tests whether giving SAR445877 together with FOLFOX6 and bevacizumab is safe and tolerable as a first-line treatment for adults with MSS metastatic colorectal cancer.

  Recruiting Phase 1 M.D. Anderson Cancer Center · Houston, Texas · NCT07500298

• Irinotecan plus cetuximab rechallenge versus trifluridine/tipiracil plus bevacizumab in metastatic colorectal cancer

  This phase 2 trial tests whether giving irinotecan with cetuximab again helps patients with metastatic colorectal cancer whose disease progressed after standard therapies, compared with the current standard third-line treatment of trifluridine/tipiracil plus bevacizumab, using blood-based molecular profiling to select

  Recruiting at 19 sites Phase 2 Gruppo Oncologico Italia Meridionale · Alessandria and 25 other locations · NCT07381764

• Ivonescimab versus bevacizumab with FOLFOX for first-line metastatic colorectal cancer

  This study tests whether ivonescimab combined with FOLFOX works as well as bevacizumab with FOLFOX for people starting first-line treatment for metastatic colorectal cancer.

  Recruiting at 243 sites Phase 3 Summit Therapeutics · Mobile, Alabama and 242 other locations · NCT07228832

• Combining node-sparing radiotherapy with chemotherapy and immunotherapy for metastatic colorectal cancer

  This study is testing a new treatment that combines a special type of radiation with chemotherapy and immunotherapy to see if it can help people with metastatic colorectal cancer live longer and feel better.

  Recruiting Phase 2/3 Sixth Affiliated Hospital, Sun Yat-sen University · Guangzhou, Guangdong · NCT06958419

• Nelmastobart plus trifluridine/tipiracil and bevacizumab for metastatic or recurrent colorectal cancer

  This trial tests whether adding nelmastobart to trifluridine/tipiracil and bevacizumab helps adults with metastatic or recurrent colorectal cancer who cannot use oxaliplatin or irinotecan.

  Recruiting Phase 1/2 STCube, Inc. · Seongnam-si, Gyeonggi-do and 4 other locations · NCT06873763

• KRAS Inhibitor ETX-929 in advanced solid tumors

  This trial tests ETX-929, alone or with cetuximab, in people whose cancers have KRAS mutations and have progressed after prior therapy.

  Recruiting Phase 1/2 Ensem Therapeutics · Fairfax, Virginia · NCT07912593

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.